NEUCHATEL, Switzerland--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) announced today the CE marking of Next Generation SedLine ® brain function monitoring for pediatric patients (1-18 years of age). With ...

In a recent breakthrough, Masimo Corporation MASI announced that its Next Generation SedLine brain function monitoring has received clearance from the FDA. The device will provide clinicians real-time ...

Masimo Corp MASI recently announced that its SedLine brain function monitor has been selected by Penn Highlands DuBois, a health centre with one of the best hospital safety scores (according to ...

(RTTNews) - Masimo (MASI) said that the U.S. FDA has cleared SedLine brain function monitoring for pediatric patients (1-17 years of age) and the SedLine Pediatric EEG Sensor. With this clearance, the ...

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) announced today FDA clearance of Next Generation SedLine ® brain function monitoring. SedLine helps clinicians monitor the state of the brain ...

Noting the unique nature of pediatric brains, which are still developing, the importance that standard anesthesia practice places on minimizing the dosage of drugs needed to maintain anesthesia, and ...

Irvine-based Masimo Corp., which makes patient monitoring devices, said a study found one of its products effectively monitored babies and toddlers undergoing surgeries. Researchers wanted to measure ...

Masimo has made a name for itself as a prolific purveyor of noninvasive patient monitoring technologies, from the SET pulse oximeter to the recently CE-marked Rainbow SuperSensor, which continuously ...

IRVINE, Calif., July 13 Masimo (Nasdaq: MASI), the inventor of Masimo Rainbow Pulse CO-Oximetry(TM), Masimo Rainbow Acoustic Monitoring(TM), and Masimo SET® Measure-Through Motion and Low Perfusion ...

(BUSINESS WIRE )--Masimo (NASDAQ: MASI) today announced the findings of a randomized clinical trial published in JAMA Pediatrics in which Dr. Yasuko Nagasaka and colleagues at Tokyo Women's Medical ...